Current Status and Problems of Photodynamic Diagnosis in Bladder Cancer

Abstract

5-aminolevulinic acid (ALA)-Photodynamic diagnosis (PDD) using ALAGLIO^® (ALA hydrochloride, SBI Pharmaceuticals Co., Ltd., Tokyo, Japan) had been approved for the management of non-muscle invasive bladder cancer (NMIBC) in Japan and has been available to the public health insurance system since 2017. ALA-PDD improved diagnostic accuracy and therapeutic effect. And ALA-induced hypotension may be observed as a side effect and need to respond.